

FIRST LIGHT

RESEARCH

Wipro | Target: Rs 840 | +25% | BUY

Strong growth and confident commentary; upgrade to BUY

Infosys | Target: Rs 2,000 | +17% | BUY

Operational beat coupled with revenue guidance upgrade

Mindtree | Target: Rs 3,390 | -22% | SELL

Upbeat Q2 but valuations lofty

SUMMARY

Wipro

- Q2 revenue growth beat estimates at 6.9% USD/8.1% CC QoQ and surpassed guided range of 5-7% CC QoQ
- Deal pipeline healthy with ACV up 28% and TCV up 19% in H1FY22. EBIT margin also outperformed at 17.8% in Q2
- Upgrade from HOLD to BUY with a new TP of Rs 840 (vs. Rs 630) given three quarters of growth outperformance

[Click here for the full report.](#)

Infosys

- Stellar Q2 with revenue growth at 5.7% USD QoQ vs. 4.2% estimated and resilient operating margin
- TCV modest at ~US\$ 2.2bn. FY22 revenue growth guidance raised to 16.5-17.5% YoY
- We tweak estimates and revise our TP to Rs 2,000 (vs. Rs 2,020); retain BUY

[Click here for the full report.](#)

Daily macro indicators

Indicator	Current	2D (%)	1M (%)	12M (%)
US 10Y yield (%)	1.58	(3bps)	24bps	85bps
India 10Y yield (%)	6.33	(2bps)	15bps	42bps
USD/INR	75.52	(0.2)	(2.7)	(2.9)
Brent Crude (US\$/bbl)	83.42	(0.3)	14.4	96.5
Dow	34,378	(0.3)	(0.7)	19.9
Shanghai	3,547	(1.2)	(4.2)	5.6
Sensex	60,284	0.2	3.4	48.4
India FII (US\$ mn)	11-Oct	MTD	CYTD	FYTD
FII-D	(87.9)	(260.5)	(185.5)	1,841.8
FII-E	(43.3)	100.6	8,630.5	1,304.2

Source: Bloomberg

BOBCAPS Research

researchreport@bobcaps.in



Mindtree

- Strong Q2 beat led by significant revenue surprise and resilient operating margin
- Management expects conducive demand dynamics to sustain growth over medium term; 20%+ FY22 EBITDA margin target unchanged
- We raise FY22-FY24 EPS by 2-4% and revise our TP to Rs 3,390 (vs. Rs 3,210). Maintain SELL on expensive valuations

[Click here](#) for the full report.

BUY

TP: Rs 840 | ▲ 25%

WIPRO

| Technology & Internet

| 14 October 2021

Strong growth and confident commentary; upgrade to BUY

- Q2 revenue growth beat estimates at 6.9% USD/8.1% CC QoQ and surpassed guided range of 5-7% CC QoQ
- Deal pipeline healthy with ACV up 28% and TCV up 19% in H1FY22. EBIT margin also outperformed at 17.8% in Q2
- Upgrade from HOLD to BUY with a new TP of Rs 840 (vs. Rs 630) given three quarters of growth outperformance

Ruchi Burde | Seema Nayak
researchreport@bobcaps.in

Growth outperformance continues: WPRO's Q2FY22 revenue grew 6.9% USD/ 8.1% CC QoQ, beating our estimate of 5.2% USD/6% CC and surpassing its guided range of 5-7% CC QoQ. Excluding Capco and Ampion, organic growth was at 4.6% CC. Most of the growth was volume-led and driven by BFSI, retail-transportation and technology which were up 11.3%, 6.9% and 6.9% USD QoQ respectively. Europe grew 50% YoY due to the Capco acquisition and ramp-up in large deals.

EBIT margin stable QoQ: At 17.8%, WPRO's EBIT margin was ahead of our estimate of 17.5%. The margin remained stable QoQ despite the full impact of the Capco and Ampion acquisitions and enhanced investments in the sales engine.

TCV robust; acquisitions continue to do well: TCV was robust at US\$ 580mn and the pipeline has a good mix of large and small sized deals. Capco had 10 deal wins in the first 100 days since acquisition. The acquisition of Ampion, an Australia-based provider of cybersecurity DevOps, was completed during the quarter.

Supply constraints to continue: Attrition increased 500bps QoQ to 20.5%. WPRO hired 11.4k employees in Q2 and has decided to take on 23k freshers in FY23. Management expects attrition to remain elevated for the next 2-3 quarters.

Q3 outlook robust: WPRO has guided for 2-4% CC QoQ growth in Q3FY22, leading to YoY growth of 27-30% CC. As per management, the demand environment is strong and cloud transformation continues to have the potential to translate into large deals. The outlook on ER&D is also optimistic as companies need to ramp up their R&D investments.

Raise to BUY: Following three quarters of growth outperformance (vs. our and consensus estimates), strong TCV and deft implementation of its new operating model, we raise WPRO's rating from HOLD to BUY. Our FY22-FY24 EPS estimates stand revised up by 1-3% post Q2 and we have a new Sep'22 TP of Rs 840 (vs. Rs 630) based on a higher one-year forward P/E multiple of 28.8x (vs. 25.5x) – a 10% discount to Infosys (INFO).

Key changes

Target	Rating
▲	▲

Ticker/Price	WPRO IN/Rs 673
Market cap	US\$ 49.3bn
Free float	26%
3M ADV	US\$ 63.3mn
52wk high/low	Rs 699/Rs 331
Promoter/FPI/DII	74%/9%/17%


Source: NSE | Price as of 13 Oct 2021

Key financials

Y/E 31 Mar	FY21A	FY22E	FY23E
Total revenue (Rs mn)	622,425	804,845	918,945
EBITDA (Rs mn)	144,560	175,583	206,233
Adj. net profit (Rs mn)	108,783	129,395	153,193
Adj. EPS (Rs)	19.7	23.4	27.7
Consensus EPS (Rs)	19.7	20.9	23.3
Adj. ROAE (%)	19.5	21.2	22.2
Adj. P/E (x)	34.2	28.7	24.3
EV/EBITDA (x)	25.0	20.4	17.3
Adj. EPS growth (%)	18.1	18.9	18.4

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE



BUY
 TP: Rs 2,000 | ▲ 17%

INFOSYS

| Technology & Internet

| 14 October 2021

Operational beat coupled with revenue guidance upgrade

- Stellar Q2 with revenue growth at 5.7% USD QoQ vs. 4.2% estimated and resilient operating margin
- TCV modest at ~US\$ 2.2bn. FY22 revenue growth guidance raised to 16.5-17.5% YoY
- We tweak estimates and revise our TP to Rs 2,000 (vs. Rs 2,020); retain BUY

Ruchi Burde | Seema Nayak
 researchreport@bobcaps.in

Stellar outperformance: INFO posted Q2FY22 revenue growth of 5.7% USD QoQ vs. our estimate of 4.2%. Growth was broad-based across verticals and spearheaded by manufacturing, life-sciences and hi-tech which grew 18.8%, 10.4% and 8.3% USD QoQ respectively. TCV was modest at ~US\$ 2.15bn, down 16% QoQ. INFO bagged 22 large deals in Q2: (1) 5 each from the financial services and energy utilities verticals, (2) 3 each from retail-CPG and manufacturing, (3) 2 each from communication and hi-tech, and (4) 1 each from life-sciences and others.

EBIT margin largely stable: EBIT margin stood at 23.6% with an inconsequential dip of 12bps QoQ as headwinds from salary hikes (110bps impact), increased subcontractor costs (50bps) were offset by tailwinds from better operational efficiency (80bps impact), cross-currency movement (30bps) and lower SG&A (50bps).

Guidance upgraded: INFO upgraded its FY22 revenue growth guidance from 14-16% CC to 16.5-17.5%, signaling a strong demand environment. The guidance factors in furlough-related softness in H2FY22. Demand remains strong, especially in cloud and digital (56% of Q2 revenue) business. EBIT margin guidance was maintained at 22-24% for FY22 amid continued supply pressures. Wage revision for senior management will adversely impact operating margins in the Dec'21 quarter.

Attrition worrisome: A continuing talent crunch saw INFO's attrition surge to a six-quarter high of 20%, up a whopping 620bps QoQ. Management is taking steps to contain attrition through (1) two rounds of compensation hikes, (2) a higher number of promotions, and (3) increased employee engagement through career development initiatives.

Maintain BUY: We adjust EPS estimates marginally and revise our Sep'22 TP from Rs 2,020 to Rs 2,000, based on an unchanged one-year forward target P/E of 32x. BUY.

Key changes

Target	Rating
▼	◀ ▶

Ticker/Price	INFO IN/Rs 1,709
Market cap	US\$ 96.6bn
Free float	3,319%
3M ADV	US\$ 130.1mn
52wk high/low	Rs 1,788/Rs 1,051
Promoter/FPI/DII	13%/33%/54%


Source: NSE | Price as of 13 Oct 2021

Key financials

Y/E 31 Mar	FY21A	FY22E	FY23E
Total revenue (Rs mn)	10,04,730	11,89,762	13,50,069
EBITDA (Rs mn)	2,79,350	3,15,578	3,54,563
Adj. net profit (Rs mn)	1,93,990	2,26,964	2,50,332
Adj. EPS (Rs)	45.5	53.9	59.5
Consensus EPS (Rs)	45.5	52.8	59.5
Adj. ROAE (%)	27.2	29.6	30.7
Adj. P/E (x)	37.5	31.7	28.7
EV/EBITDA (x)	25.4	22.4	20.1
Adj. EPS growth (%)	16.7	18.5	10.3

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE



SELL
 TP: Rs 3,390 | ▼ 22%

MINDTREE

| Technology & Internet

| 14 October 2021

Upbeat Q2 but valuations lofty

- Strong Q2 beat led by significant revenue surprise and resilient operating margin
- Management expects conducive demand dynamics to sustain growth over medium term; 20%+ FY22 EBITDA margin target unchanged
- We raise FY22-FY24 EPS by 2-4% and revise our TP to Rs 3,390 (vs. Rs 3,210). Maintain SELL on expensive valuations

Ruchi Burde | Seema Nayak
 researchreport@bobcaps.in

Growth outperforms: MTCL's Q2FY22 revenue grew 12.8% QoQ USD, well above our and consensus estimates of 7.5%. Growth was broad-based across verticals, led by travel/manufacturing & retail which increased 14.4%/29.6% QoQ USD. Part of retail & CPG revenue growth was seasonal as the top 6 to 20 clients in this vertical are from Europe. BFSI continued to build on the recovery seen in Q1 with 8.4% USD growth. MTCL's investment in Europe has fructified with the geography growing 36.4% QoQ. Top client growth was flat QoQ but up 12.8% YoY. TCV was somewhat muted at US\$ 360mn, declining 28.6% QoQ (+18.8% YoY).

Supply challenges raise attrition: MTCL's operating margin was resilient despite the wage hike impact and challenging talent market. EBITDA margin stood at 20.5%, up 20bps QoQ. EBIT margin rose 50bps QoQ to 18.2%, ahead of our estimate of 18%. The 20bps tailwind can be broken down as follows: (1) 190bps tailwind from robust growth and higher operational efficiency, (2) 140bps headwind from wage hikes, and (3) 30bps headwind from cross-currency movement. The company hired 4,400 employees in Q2 to backfill attrition which climbed to 17.7% (+400bps QoQ and YoY). Utilisation levels normalised to 82.9%, down 30bps QoQ.

Strong medium-term demand outlook: Management believes the near-to-medium term demand environment remains robust. Technology has become central to clients' strategy and their IT spending focus has now shifted from maximising cost efficiency to maximising revenue growth.

Robust strategy: MTCL will continue to invest towards enhancing its digital and marketing capabilities. It remains focused on reducing top client concentration and diversifying the client base through cross-selling, upselling and new logo addition.

Maintain SELL: We increase FY22/FY23/FY24 EPS by 4%/2%/2% to factor in the Q2 operational beat and raise our target P/E to 36x (five-year avg. P/E + 3 std. deviations) vs. 30x earlier led by the upbeat demand climate. This yields a new Sep'22 TP of Rs 3,390. While we acknowledge MTCL's strong operational dynamics, valuations at 46.3x/43.6x FY22E/FY23E PE are lofty and leave limited scope for further upside.

Key changes

Target	Rating
▲	◀ ▶

Ticker/Price	MTCL IN/Rs 4,364
Market cap	US\$ 9.5bn
Free float	87%
3M ADV	US\$ 64.5mn
52wk high/low	Rs 4,734/Rs 1,262
Promoter/FPI/DII	74%/11%/15%


Source: NSE | Price as of 13 Oct 2021

Key financials

Y/E 31 Mar	FY21A	FY22E	FY23E
Total revenue (Rs mn)	79,678	103,469	119,833
EBITDA (Rs mn)	16,426	21,576	24,266
Adj. net profit (Rs mn)	11,103	15,492	16,490
Adj. EPS (Rs)	67.4	94.1	100.2
Consensus EPS (Rs)	67.4	85.6	99.0
Adj. ROAE (%)	29.7	33.0	29.8
Adj. P/E (x)	64.7	46.4	43.6
EV/EBITDA (x)	43.5	33.0	29.2
Adj. EPS growth (%)	76.0	39.5	6.4

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE



Disclaimer

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%

HOLD – Expected return from -6% to +15%

SELL – Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Rating distribution

As of 30 September 2021, out of 105 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 48 have BUY ratings, 25 have HOLD ratings, 10 are rated ADD*, 2 are rated REDUCE* and 20 are rated SELL. None of these companies have been investment banking clients in the last 12 months. (*Our ADD and REDUCE ratings are in the process of being migrated to the new recommendation structure.)

Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017. BOBCAPS CIN Number: U65999MH1996GOI098009.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed

in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.